Abstract
The first successful transplants of hematopoietic stem cells were done in 1968 in three children with congenital immune deficiency diseases. In each instance, stem cells were collected from the bone marrow of sibling donors who were genotypically HLA identical or closely HLA matched to the recipient. Since then, thousands of patients have received hematopoietic stem cell transplants to treat malignant and non-malignant diseases. Current estimates of annual numbers of stem cell transplants are about 50,000 worldwide, with growth at a rate of 10–15% per year. The reasons for increasing use include proven and potential efficacy in many diseases, better understanding of the appropriate timing of transplantation and patient selection, greater availability of donors and better techniques for determining HLA match, greater ease of stem cell collection, and improved supportive care resulting in less transplant-related morbidity and mortality. About two-thirds of hematopoietic stem cell transplants use autologous cells, generally collected from peripheral blood by leukapheresis. The remainder are allogeneic transplants, most commonly from HLA-identical sibling donors, and most often using cells collected directly from bone marrow.
Similar content being viewed by others
References
Bach FH, Albertini RJ, Joo P, et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome.Lancet. 1968;2:1364–1366.
Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked immunological deficiency.Lancet. 1968;2:1366–1369.
Good RA, Meuwissen HF, Hong R, et al. Successful marrow transplantation for correction of immunological deficit in lymphopenic agammaglobulinemia and treatment of immunologically induced pancytopenia.Exp Hematol. 1969;19:4–10.
Niland, JC, Gebhardt JA, Lee J, et al. Study design, statistical analyses, and results reporting in the bone marrow transplantation literature.Biol Blood Marrow Transplant. 1995; 1:47–53.
Begg CB. Selection of patients for clinical trials.Semin Oncol. 1988;15:434–50.
Schmucker DL, Vesell ES. Underrepresentation of women in clinical drug trials.Clin Pharm Therap. 1993;54:11–15.
Gorkin L, Schron EB, Handshaw K, et al. Clinical trial enrollers vs. Nonenrollers: the Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project.Controlled Clinical Trials. 1996;17:46–59.
Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials.Ann Intern Med 1983;99:544–550.
Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood. 1992;79:3067–3070.
Mugishima H, Gale RP, Rowlings PA, et al. Bone marrow transplantation for Diamond-Blackfan anemia.Bone Marrow Transplant. 1995;15:55–58.
Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia.Ann Intern Med. 1996;124: 311–315.
Harrell FE, Lee KL, Matchar DB, et al. Regression models for prognostic prediction: Advantages, problems, and suggested solutions.Cancer Treat Rep. 1985;69:1071–1077.
Simon R, Altman DG: Statistical Aspects of prognostic factor studies in oncology.Br J Cancer. 1994;69:979–985.
Gale RP, Bortin MM, van Bekkum DW, et al. Risk factor for acute graftvshost disease.Br J Haematol. 1988;67:397–406.
Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-vs-host disease after HLA-identical sibling bone marrow transplantation.Blood. 1990;75:2459–2464.
Weiner RS, Bortin MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation: Assessment of risk factors.Ann Intern Med. 1986;104:168–175.
Weiner RS, Horowitz MM, Gale RP, et al. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anemia.Br J Haematol. 1989;71:535–543.
Gale RP, Horowitz M, Bortin M. IBMTR analysis of bone marrow transplants in acute leukemia.Bone Marrow Transplant. 1990;4:8385.
Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission.Bone Marrow Transplant. 1995;16:203–208.
Barrett AJ, Horowitz MM, Gale RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival.Blood. 1989;74:862–871.
Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with Tcell depletion.Ann Intern Med. 1988;108:806–814.
Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results.Blood. 1989;73:606–613.
Rowlings PA, Williams SF, Antman KH, et al. Factors correlated with progression-free survival after high-dose therapy and hematopoietic stem cell transplantation for metastatic breast cancer.JAMA. 1999;282:1335–1343.
Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.Blood. 1992;79:269–275.
Ringdn O, Horowitz MM, Sondel P, et al. Methotrexate, cyclo-sporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?Blood. 1993;81:1094–1101.
Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.J Clin Oncol. 1997;15:1767–1777.
Davies SM, Ramsay NKC, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.J Clin Oncol. 2000;18:340–347.
Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia.Blood. 1991;78: 2120–2130.
Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.Blood. 2000;95:3996–4003.
Klein JP, Zhang MJ. Statistical challenges in comparing chemotherapy and bone marrow transplantation as a treatment for leukemia, in Jewel, Kimber, Lee, Whitmore (eds):Lifetime Data: Models in Reliability and Survival Analysis, pp 175–186.
Kulwar Academic Press, Norwell, MA, 1996.
Gale RP, Bchner T, Zhang MJ, et al. HLA-identical sibling bone marrow transplantsvs chemotherapy for acute myelogenous leukemia in first remission.Leukemia. 1996;10:1687–1691.
Gale RP, Horowitz MM, Rees JKH, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission.Leukemia. 1996;10:13–19.
Horowitz MM, Messerer D, Hoelzer D, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission.Ann Intern Med. 1991;115:13–18.
Zhang MJ, Hoelzer D, Horowitz MM, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation.Ann Intern Med. 1995;123:428–431.
Oh H, Gale RP, Zhang MJ, et al. Chemotherapy versus HLA-identical sibling transplants for adults with acute lymphoblastic leukemia in first remission.Bone Marrow Transplant. 1998; 22:253–257.
Barrett AJ, Horowitz MM, Pollock BH, et al. Bone Marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission.N Engl J Med. 1994;331:1253–1258.
Gale RP, Hehlmann R, Zhang MJ, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia.Blood 1998;91:1810–1819.
Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry (submitted).
Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation.New Engl J Med. 1997;336: 897–904.
Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin disease following allogeneic bone marrow transplant.J Clin Oncol. 1999;17:3122–3127.
Soci G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.J Clin Oncol. 2000;18:348–357.
Soci G, Veum-Stone J, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation.New Engl J Med. 1999;341:14–21.
Anderson PK, Klein JP, Zhang MJ. Testing for center effects in multicenter survival studies: a Monte Carlo comparison of fixed and random effects.Statist Med. 1999;18:1489–1500.
Klein JP, Zhang M. Technical Report #12: Confidence regions for the equality of two survival curves. July, 1996.
Klein JP, Keiding N, Shu Y, et al. Summary curves for patients transplanted for chronic myeloid leukemia salvaged by a donor lymphocyte infusion: the current leukemia free survival curve.Br J Haematol. 2000;109:148–152.
Klein JP, Szydlo RA, Craddock C, et al. Estimation of current leukemia-free survival following donor lymphocyte infusion therapy for patients with leukemia who relapse after allografting: application of a multistate model.Statistics in Medicine. 2000;19:3005–3016.
Pocock SJ, Elbourne DR. Randomized trials or observational tribulations?N Engl J Med. 2000;355:1907–1909.
Soci G, Veum-Stone J, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation.New Engl J Med. 1999;341:14–21.
Author information
Authors and Affiliations
About this article
Cite this article
Goldman, J.M., Horowitz, M.M. The International Bone Marrow Transplant Registry. Int J Hematol 76 (Suppl 1), 393–397 (2002). https://doi.org/10.1007/BF03165291
Issue Date:
DOI: https://doi.org/10.1007/BF03165291